Status:
COMPLETED
T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Breast Cancer
Lung Cancer
Eligibility:
All Genders
Phase:
NA
Brief Summary
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment. It may also help the study of cancer in the futur...
Detailed Description
OBJECTIVES: * Assess T-cell activation in blood samples of patients receiving trastuzumab (Herceptin®) and/or chemotherapy for HER2-positive solid tumors. OUTLINE: Blood samples are collected from p...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of solid epithelial tumor, including, but not limited to, the following:
- Breast cancer
- Ovarian cancer
- Lung cancer
- Uterine cancer
- Prostate cancer
- HER2/neu-positive disease by immunohistochemistry or fluorescent in situ hybridization
- Must be receiving trastuzumab (Herceptin®) and/or chemotherapy (e.g., paclitaxel, docetaxel, fluorouracil, or estramustine)
- PATIENT CHARACTERISTICS:
- Absolute neutrophil count \> 1,000/mm\^3
- Absolute lymphocyte count \> 400/mm\^3
- Platelet count \> 90,000/mm\^3
- Hemoglobin \> 8 g/dL
- PRIOR CONCURRENT THERAPY:
- No other chemotherapy within the past 4 weeks
Exclusion
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00433407
Start Date
August 1 2005
Last Update
October 4 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California, United States, 90095-1781